Cipla Ltd. — Capital/Financing Update 2019

Feb 18, 2019

18th February 2019

• (1) BSE Ltd Listing Department Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai - 400 001
• (2) National Stock Exchange of India Ltd Listing Department Exchange Plaza, 5th floor, Plot no. C/1, G Block, Sandra Kurla Complex, Sandra (East), Mumbai - 400 051

Scrip Code: 500087

Scrip Code: CIPLA EQ

(3) SOCIETE DE lA BOURSE DE LUXEMBOURG Societe Anonyme 35A Boulevard Joseph II, L-1840 Luxembourg

Dear Sirs,

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform that the Company's wholly owned subsidiary Goldencross Pharma Private Limited has signed an agreement on 18th February 2019, to acquire 11.71 % stake in Wellthy Therapeutics Private Limited ("Wellthy").

The details as required under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 are enclosed as Annexure- I.

In addition, the Company has signed service agreement with Wellthy. The related Press Release is enclosed.

Thank you,

dra Chopra Company Secretary

Encls:

• 1. Details as per the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
• 1. Press Release

Prepared by: Kamlesh Kulkarni

Annexure -I

Sr.	Particulars	Details
No.
a)	Name of the target entity, details in brief such as size, turnover etc.;	Wellthy Therapeutics Private Limited ["Wellthy"] It has turnover of Rs 12,04,015 for the financial year ending on 31 51 March 2018.
b)	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arms length";	Acquisition doesn't fall within the purview of related party transactions.
c)	Industry to which the entity being acquired belongs;	Digital therapeutics: Digital therapeutics (DTx) deliver evidence-based therapeutic interventions to patients that are driven by software + human programs to prevent, manage, or treat a medical disorder or disease. They are used independently or in concert with medications, devices, or other therapies to optimize patient care and health outcomes.
d)	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity);	Cipla launched lnnoventia FY19, an in innovation challenge to fund and incubate disruptive ideas in healthcare. This was an attempt to involve a large set of people in solving unmet patient needs. As part of that challenge, Wellthy's digital therapeutics has been shortlisted as one of the most revolutionary ideas. As part of the commitment extended to supporting and mentoring start-ups, the Company's WOS Goldencross Pharma Pvt Ltd is taking minority equity stake in Wellthy.

e)	Brief details of any governmental	NA
	or regulatory approvals required
	for the acquisition;
f)	Indicative time period for	The transaction expected to be completed
	completion of the acquisition	before 1 01 h March 2019
g)	Nature of consideration - whether	Cash consideration
	cash consideration or share swap
	and details of the same;
h)	Cost of acquisition or the price at	Cash consideration of Rs. 10.5 Crores (Indian
	which the shares are acquired	Rupees Ten Crores Fifty Lakhs Only) to be paid
		on closing of the transaction.
i)	Percentage of shareholding I	532,121 Compulsory Convertible Preference
	control acquired and I or number	Shares (CCPS) of Rs 197.32 each and 10 equity
	of shares acquired;	shares of Rs 197.32 each, representing 11.71%
		stake in Wellthy on a fully diluted basis.
j)	Brief background about the entity	Wellthy was incorporated on 2nd December 2015
	acquired in terms of products/line	in India and is engaged in the business of digital
	of business acquired, of date	therapeutics for chronic disease management.
	history of last 3 incorporation,	The entity has its operations only in India as of
	years turnover, country in which	Wellthy's now. turnover for FY18 is Rs
	the acquired entity has presence	12,04,015; FY17: Rs NIL; FY16 Rs NIL
	and any other significant
	information (in brief)

Press Release

Cipla and Wellthy Therapeutics Announce Partnership to offer Digital Therapeutics for Diabetes and Cardiovascular Diseases

Mumbai, February 18, 2019: Cipla Limited (BSE: 500087; NSE: CIPLA EQ; and hereafter referred to as "Cipla") and Wellthy Therapeutics Private Limited ("Wellthy Therapeutics") today announced that they have entered into a partnership to offer a combination of pharmacotherapy and digital therapeutics for improved patient outcomes in the chronic therapies of diabetology and cardiology.

Under the agreement, a multi-lingual clinically-validated digital disease management platform will be made available to patients living with diabetes or cardiovascular diseases via doctors' clinics or co-packaging on select Cipla brands. The platform brings together behavioural science, real world clinical evidence and artificial intelligence to provide real time monitoring, coaching and advice to patients, and virtual clinical assistance to doctors.

This partnership is a result of Cipla's campaign, lnnoventia, which was envisioned as a first-of-its-kind challenge by an Indian pharmaceutical company to encourage innovation-led entrepreneurship and to harness disruptive ideas in healthcare to fulfil unmet patient needs.

Umang Vohra, MD & Global CEO of Cipla, said, "The future of healthcare will be driven by increased use of technology, and this partnership gives Cipla the ability to offer this combination of ·prescription drugs and artificial intelligence-powered digital therapeutics to patients in cardio-metabolic health. It will allow patients to make informed decisions and take charge of their own health. By pairing our pharmacotherapy strengths with the digital approach to healthcare taken by Wellthy Therapeutics, Cipla will add to its diversified portfolio in the cardio-metabolic area to provide holistic care to patients from awareness, diagnosis and compliance to wellbeing."

Abhishek Shah, Co-founder & CEO of Wellthy Therapeutics, said, "We are excited to work with Cipla to bring digital therapeutics to patients in India. Companion digital therapeutics are redefining the treatment of chronic conditions, by helping personalise and simplify disease management for patients, and driving precision clinical insights to clinicians. With the combination of Cipla's world class formulations and clinically validated digital therapeutics of Wellthy Therapeutics, we look forward to helping empower and inspire millions of patients to achieve better, sustainable health outcomes."

Cardiovascular Diseases (CVDs) are the leading cause of mortality in India today. cutting across the urban-rural divide. Diabetes and hypertension are significant risk factors leading to CVDs. Over 72 million1 Indians are estimated to be diabetic while approximately 1 0% of the population is estimated to be pre-diabetic2, and 29% of the population is estimated to be hypertensive3.

About Cipla Limited

Established in 1935, Cipla is a global pharmaceutical company focused on agile and sustainable growth, complex generics, and deepening portfolio in our home markets of India, South Africa, North America, and key regulated and emerging markets. Our strengths in the respiratory, anti-retroviral. urology, cardiology and CNS segments are well-known. Our 44 manufacturing sites around the world produce 50+ dosage forms and 1 ,500+ products using cutting-edge technology platforms to cater to our 80+ markets. Cipla is ranked 3rd largest in pharma in India (IQVIA MAT Dec'18), 3rd largest in the pharma private market in South Africa (IQVIA YTD Dec' 18), and is among the most dispensed generic players in the US. For over eight decades, making a difference to patients has inspired every aspect of Cipla's work. Our paradigm-changing offer of a triple anti-retroviral therapy in HIV I AIDS at less than a dollar a day in Africa in 2001 is widely acknowledged as having contributed to bringing inclusiveness. accessibility and afford ability to the centre of the movement. A responsible corporate citizen, Cipla's humanitarian approach to healthcare in pursuit of its purpose of 'Caring for Life' and deep-rooted community links wherever it is present make it a partner of choice to global health bodies. peers and all stakeholders. For more, please visit www.cipla.com, or click on Twitter. Facebook, Linkedln.

Corporate Communications

Investor Relations

Heena Kana! E-mail: CorpComm@c ipla.com Naveen Bansal E-mail: lnvestor.Relations@clpla.com

¹ As per data gathered by IDF in 2017: https:L/www.idf.org/our-network/regions-members/south-east-

asia/members/94-india.html 2 The study was published for the period of 2008-2011 and was recently referred to in the Lancet in 2017: https://lcmr.nic.in/sites/default/files/reports/ICMR INDIAB PHASE I FINAL REPORT.pdf & htt.ps://www. t helancet.com/jou rnals/la ndia/article/PII 2213-8587{17)30174-2/fulltexl

³ Source: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4011S65/

About Wellthy Therapeutics Private Limited

Wellthy Therapeutics is a digital therapeutics company that inspires and enables patients to prevent, reverse and control chronic diseases. It's first digital therapeutic for Type II diabetes has been endorsed by Asia's largest diabetes association (RSSDI). Wellthy Therapeutics has published & presented real-world data at the AACE 26th Annual Congress in Austin and the AACE 27th Annual Congress in Boston, the ADA 77th Scientific Sessions in San Diego and the ADA 78th Scientific Sessions in Florida, the the IDF Congress 2017 in Abu Dhabi. the ATID 11th International Conference in Vienna and soon the ATID 12¹ h International Conference in Berlin, AADE Annual Conference in Baltimore, Maryland, the RSSDI 44'h, 45'h and 46'h Annual conferences in India, and the 12th RSSDI Regional Conference in India. For more information, visit www.wellthy.core, or follow us on Linkedin or Facebook.

Corporate Communications

Reshma Nayak E-mail: corpcomm@wellthy.care